SC-2550 U NATURAL SC-2551 G BLUE SC-2549 U RED

116UGNS PANTONE(R) 116 U SIMULATION DB1541D MED BLUE PMS 300 466UGNS PANTONE(R) 466 U SIMULATION

STAN-TONE HCC-108786 LIGHT TAN H #2 STAN-TONE HCC-108787 DARK BROWN H #1 STAN-TONE HCC-108789 DARK BROWN H #2

BLUE PIGMENT H. H.

PS BLUE WHITE BEACH H&S PMS 413 BEACH H&S PMS 428

D is t. ) K W R R P M P P G A V Y F U L G C P IF F H X L F M C F O E H U N E C L K R A E M N A S H C E S C L G R A A LB Median: 5%Median: 3% Source: Peer data per Bloomberg market data as of April 27, 2021 Avient reflects 2021 estimated revenue of $4,300M and excludes one-time synergy capture CAPEX ($20M) Avient Specialty Formulators Other Chemical/Specialty Companies Free Cash Flow Conversion (1) 2021E (%) Being asset light helps us to generate strong free cash flow that is in line with specialty formulators. Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA Median: 84% Median: 77% HIGH FREE CASH FLOW CONVERSION Avient reflects 2021 estimated EBITDA of $560M and excludes one-time synergy capture CAPEX ($20M) Source: Peer data per Bloomberg market data as of April 27, 2021 87 89 87 86 82 81 76 88 87 84 82 81 78 77 77 77 76 73 70 69 50 19 A vi en t K W R P P G R P M A V Y F U L G C P F M C IF F H X L U N V R E C L A S H C E B N R F O E E M N G R A H U N K R A S C L A L B Source: Peer data per Bloomberg market data as of April 27, 2021 Total Enterprise Value / 2021E EBITDA Our current valuation with updated guidance implies an EBITDA multiple that is below specialty formulator peers and the majority of our chemical peers. With the Clariant Masterbatch acquisition and divestment of the PP&S business, our exposure is now concentrated in less-cyclical and high-growth markets, with increased geographic diversification and a more specialized portfolio that can significantly expand EBITDA margins. 20 Avient reflects 2021 estimated EBITDA of $560M OUR VALUATION VERSUS PEERS Avient Specialty Formulators Other Chemical/Specialty Companies 10.2 17.7 16.0 14.9 14.6 11.6 11.1 26.7 24.0 22.8 14.3 12.7 11.5 11.2 11.1 11.0 10.3 10.1 9.5 9.4 8.3 7.0 A vi en t K W R A V Y R P M P P G G C P F U L A L B H X L E C L IF F F M C B N R A S H G R A F O E S C L E M N U N V R C E K R A H U N Median: 11.1xMedian: 14.8x SUMMARY: WHY INVEST IN AVIENT?

MB SLD 542C SH/HO EPIC COLUMBIA BLUE 306ULBFF EPIC PANTONE(R) 306 U HO SIM STAN-TONE DB-15597 HI LITE BLUE

424ULBFF EPIC PANTONE(R) 424 U HO SIM STAN-TONE HCC- BLUE STAN-TONE DB-15597 HI LITE BLUE

NYSE: AVNT) AVIENT CORPORATION S P E C I A LT Y P O R T F O L I O T R A N S F O R M AT I O N C O N T I N U E S W I T H D Y N E E M A A C Q U I S I T I O N 2 0 2 2 F I R S T Q U A R T E R R E S U LT S DISCLAIMER 2 Forward-Looking Statements In this presentation, statements that are not reported financial results or other historical information are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. F I RS T Q UART E R 2022 RE S U LT S $123 $136 2021 2022 $0.89 $0.99 2021 2022 Q1 2022 PERFORMANCE (TOTAL COMPANY) 4 $1,162 $1,294 2021 2022 + 11% (+ 14% excluding FX) Adjusted EPS + 11% (+ 15% excluding FX) + 11% (+ 16% excluding FX) (in millions) (in millions) Sales Adjusted Operating Income Q1 2022 SEGMENT PERFORMANCE 5 CAI $609 $650 Sales ($ in millions) SEM Distribution $89 $95 Operating Income + 7% (+ 10% excluding FX) $363 $433 Sales $24 $24 Operating Income + 19% Flat (1) $217 $245 Sales $34 $40 Operating Income + 7% (+ 11% excluding FX) + 13% (+ 17% excluding FX) + 18% (+ 20% excluding FX) Q1 2021 $1,162 $123 Sustainable Solutions 19 8% 7 Healthcare 32 21% 6 Composites (excl. Purchase price multiple rapidly declining on strength of business and synergy capture (1) (1) (1) Financial information is pro forma to include a full year of Clariant Color acquisition ($ in millions) 11.9% 16.2% 2019PF 2021 EBITDA Margins (1) SPECIALTY TRANSFORMATION 7% 46% 66% 86% 100% 0% 20% 40% 60% 80% 100% 2005 2010 2015 2021 2022 PF % o f A dj us te d EB IT D A(1 ) JVs Distribution Performance Products & Solutions Specialty (1) Adjusted EBITDA is EBITDA excluding corporate costs and special items (2) Pro forma for the acquisition of Dyneema® and potential divestiture of Distribution (2) 29 12% 18% 16% 15% 15% 14% 14% 28% 28% 26% 25% 22% 21% 19% 16% 12% 9% 9% Av ie nt T od ay Av ie nt P F AV Y PP G KW R FU L R PM C E AL B FM C AS H EC L EM N H XL H U N SC L BN R U N VR Median: 21%Median: 15% 2022 EBITDA MARGINS VS.

Microsoft PowerPoint - AVNT June IR Conferences_6.1.2023 1130AM AVIENT CORPORATION I N V E S T O R P R E S E N T A T I O N (NYSE: AVNT) J U N E 2 0 2 3 DISCLAIMER Forward-Looking Statements Certain statements contained in or incorporated by reference into this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Avient Specialty Formulators Other Specialty / Chemical Companies 2023E(%) 37 79 89 83 81 76 73 90 82 77 76 74 70 58 22 A vi en t K W R P P G F U L A V Y R P M F M C C E H X L A S H E C L H U N E M N S C L MULTIPLE EXPANSION Avient Specialty Formulators Other Specialty / Chemical Companies Source: Peer data per Bloomberg as of May 31, 2023 Note: Avient reflects 2023 adjusted EBITDA guidance of $530M and closing share price of $36.50. Avient 2011 and 2018 valuations reflect trailing 12 months EBITDA at December 31 of the respective years. 38 EV / 2023E EBITDA Historic Multiple 6.5 8.3 9.6 13.2 13.0 12.8 11.3 8.6 17.9 16.8 10.7 8.8 8.8 8.7 7.5 6.9 A vi en t (2 01 1) A vi en t (2 01 8) A vi en t (2 02 3) K W R P P G R P M A V Y F U L E C L H X L F M C S C L C E A S H E M N H U N Reconciliation of Non-GAAP Financial Measures (Unaudited) (Dollars in millions, except for per share data) Senior management uses comparisons of adjusted net income from continuing operations attributable to Avient shareholders and diluted adjusted earnings per share (EPS) from continuing operations attributable to Avient shareholders, excluding special items, to assess performance and facilitate comparability of results.